边界可切除胰腺癌新辅助治疗的机遇与挑战  

Neoadjuvant Therapy for Borderline Resectable Pancreatic Cancer:Opportunity and Challenges

作　　者：徐有耀 陈益臻 吴嘉 韩方 张宇华 XU You-yao;CHEN Yi-zhen;WU Jia;HANG Fan;ZHANG Yu-hua(School of the Second Clinical Medical College,Zhejiang Chinese Medical University,Hangzhou 310053,China;The Cancer Hospital of The University of Chinese Academy of Sciences(Zhejiang Cancer Hospital),Institute of Basic Medicine and Cancer(IBMC),Chinese Academy of Sciences,Hangzhou 310022,China)

机构地区：[1]浙江中医药大学第二临床医学院,浙江杭州310053 [2]中国科学院大学附属肿瘤医院(浙江省肿瘤医院),中国科学院基础医学与肿瘤研究所,浙江杭州310022 [3]中国科学院大学附属肿瘤医院(浙江省肿瘤医院)肝胆外科,浙江省杭州市310022

出　　处：《肿瘤学杂志》2021年第10期823-828,共6页Journal of Chinese Oncology

摘　　要：胰腺癌在腹部常见恶性肿瘤中预后最差,根治性手术切除是唯一可能治愈的方法。然而,越来越多的研究结果证实新辅助治疗能改善边界可切除胰腺癌(BRPC)的预后。目前,BRPC的主要治疗方式是新辅助治疗后手术切除肿瘤。全文就BRPC新辅助治疗的发展历程、理论基础、化疗方案、疗效评估及手术时机等方面进行综述。Pancreatic cancer is a common abdominal malignancy with poor prognosis,and radical surgical resection is the only potential curative treatment for pancreatic cancer.However,an increasing number of studies have demonstrated that neoadjuvant therapy is beneficial in patients with borderline resectable pancreatic cancer(BRPC).At present,the main treatment for patients with BRPC is neoadjuvant therapy followed by surgical resection.This article reviews the development,theoretical basis,chemotherapy regimen,efficacy evaluation and operation timing of neoadjuvant therapy for BRPC.

关 键 词：新辅助治疗 手术时机 胰腺癌 疗效评估 常见恶性肿瘤 手术切除 BRP 机遇与挑战 

分 类 号：R735.9[医药卫生—肿瘤]